Clinical Trial

Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2025 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.
Trial Details
NCT Number NCT06783166
Lead Sponsor Mansoura University
Conditions Acute Heart Failure
Enrollment 100 participants
Start Date 2024-08-15
Primary Completion 2025-07-01 (estimated)
Study Completion 2025-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-20